Chapter 4 Therapeutic Approaches to Ion Channel Diseases

Advances in Genetics

Volumn 64, Issue , 2008, Pages 81-145

  Camerino, Diana Conte ^a   Desaphy, Jean François ^a   Tricarico, Domenico ^a   Pierno, Sabata ^a   Liantonio, Antonella ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL; POTASSIUM CHANNEL; SODIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

AUTOIMMUNE DISEASE; CHANNELOPATHY; DRUG EFFECT; HUMAN; MALIGNANT HYPERTHERMIA; MUSCLE DISEASE; MYOTONIA; MYOTONIC DYSTROPHY; NEUROMUSCULAR JUNCTION DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SKELETAL MUSCLE;

AUTOIMMUNE DISEASES; CHANNELOPATHIES; HUMANS; ION CHANNELS; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOTONIA; MYOTONIC DYSTROPHY; NEUROMUSCULAR JUNCTION DISEASES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; SODIUM CHANNELS;

EID: 58249084640     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2660(08)00804-3     Document Type: Chapter

References (234)

1. Accardi A., and Pusch M. Conformational changes in the pore of CLC-0. J. Gen. Physiol. 122 (2003) 277-293
2. Accurso F.J. Update in cystic fibrosis 2007. Am. J. Respir. Crit. Care Med. 177 (2008) 1058-1061
3. Annane D., Moore D.H., Barnes P.R., and Miller R.G. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. Cochrane Database Syst. Rev. 3 (2006) CD003218
4. Argov Z., McKee D., Agus S., Brawer S., Shlomowitz N., Yoseph O.B., Soreq H., and Sussman J.D. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 69 (2007) 699-700
5. Arneric S.P., Holladay M., and Williams M. Neuronal nicotinic receptors: A perspective on two decades of drug discovery research. Biochem. Pharmacol. 74 (2007) 1092-1101
6. Arnestad M., Crotti L., Rognum T.O., Insolia R., Pedrazzini M., Ferrandi C., Vege A., Wang D.W., Rhodes T.E., George Jr. A.L., and Schwartz P.J. Prevalence of Long-QT syndrome gene variants in sudden infant death syndrome. Circulation 115 (2007) 361-367
7. Aromataris E.C., Astill D.S., Rychkov G.Y., Bryant S.H., Bretag A.H., and Roberts M.L. Modulation of the gating of ClC-1 by S-(-) 2-(4-chlorophenoxy)propionic acid. Br. J. Pharmacol. 126 (1999) 1375-1382
8. Ashcroft F.M. From molecule to malady. Nature 440 (2006) 440-447
9. Askmyr M.K., Fasth A., and Richter J. Towards a better understanding and new therapeutics of osteopetrosis. Br. J. Haematol. 140 (2008) 597-609
10. Attal N., Cruccu G., Haanpaa M., Hansson P., Jensen T.S., Numikko T., Sampaio C., Sindrup S., and Wilfen P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13 (2006) 1153-1169
11. Ayata C., Hongwei J., Kudo C., Dalkara T., and Moskowitz M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59 (2006) 652-661
12. Bakker M.J., van Dijk J.G., van den Maagdenberg A.M.J.M., and Tijssen M.A. Startle syndromes. Lancet Neurol. 5 (2006) 513-524
13. Barlassina C., Dal Fiume C., Lanzani C., Manunta P., Guffanti G., Ruello A., Bianchi G., Del Vecchio L., Macciardi F., and Cusi D. Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension. Hum. Mol. Genet. 16 (2007) 1630-1638
14. Belhassen B., Glick A., and Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110 (2004) 1731-1737
15. Bellinger A.M., Mongillo M., and Marks A.R. Stressed out: The skeletal muscle ryanodine receptor as a target of stress. J. Clin. Invest. 118 (2008) 445-453
16. Benhorin J., Taub R., Goldmit M., Kerem B., Kass R.S., Windman I., and Medina A. Effects of flecainide in patients with new SCN5A mutation: Mutation-specific therapy for long-QT syndrome?. Circulation 101 (2000) 1698-1706
17. Benos D.J. Amiloride: A molecular probe of sodium transport in tissues and cells. Am. J. Physiol. 242 (1982) C131-C145
18. Bezzina C.R., and Tan H.L. Pharmacological rescue of mutant ion channels. Cardiovasc. Res. 55 (2002) 229-232
19. Bien C.G., Granata T., Antozzi C., Cross J.H., Dulac O., Kurthen M., Lassmann H., Mantegazza R., Villemure J.G., Spreafico R., and Elger C.E. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement. Brain 128 (2005) 454-471
20. Birkenhäger R., Otto E., Schurmann M.J., Vollmer M., Ruf E.-M., Maier-Lutz I., Beekmann F., Fekete A., Omran H., Feldmann D., Milford D.V., Jeck N., et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat. Genet. 29 (2001) 310-314
21. Boneva N., Frenkian-Cuvelier M., Bidault J., Brenner T., and Berrih-Aknin S. Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis. J. Neuroimmunol. 177 (2006) 119-131
22. Bongioanni P., Ricciardi R., and Romano M.R. T-lymphocyte interferon-gamma receptor binding in patients with myasthenia gravis. Arch. Neurol. 56 (1999) 933-938
23. Bryant S.H., and Conte Camerino D. Chloride channel regulation in the skeletal muscle of normal and myotonic goats. Pflügers Arch. 417 (1991) 605-610
24. Bryant S.H., and Morales-Aguilera A. Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids. J. Physiol. 219 (1971) 367-383
25. Buckley C., and Vincent A. Autoimmune channelopathies. Nat. Clin. Pract. Neurol. 1 (2005) 22-33
26. Cebotaru V., Kaul S., Devuyst O., Cai H., Racusen L., Guggino W.B., and Guggino S.E. High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent's disease. Kidney Int. 68 (2005) 642-652
27. Celesia G.G. Disorders of membrane channels or channelopathies. Clin. Neurophysiol. 112 (2001) 12-18
28. Chaitman B.R. Ranolazine for the treatment of chronic angina and potential se in other cardiovascular conditions. Circulation 113 (2006) 2462-2472
29. Chalhoub N., Benachenhou N., Rajapurohitam V., Pata M., Ferron M., Frattini A., Villa A., and Vacher J. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat. Med. 9 (2003) 399-406
30. Chang S.S., Grunder S., Hanukoglu A., Rösler A., Mathew P.M., Hanukoglu I., Schild L., Lu Y., Shimkets R.A., Nelson-Williams C., Rossier B.C., and Lifton R.P. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet. 12 (1996) 248-253
31. Chen H.S., and Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97 (2006) 1611-1626
32. - channel 1 gene dosage. J. Physiol. 504 (1997) 75-81
33. Chen Y., Lu J., Pan H., Zhang Y., Wu H., Xu K., Liu X., Jiang Y., Bao X., Yao Z., Ding K., Lo W.H., et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann. Neurol. 54 (2003) 239-243
34. Christie S., Gobel H., Mateos V., Allen C., and Vrijens F. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur. Neurol. 49 1 (2003) 20-29
35. Clare J.J., Tate S.N., Nobbs M., and Romanos M.A. Voltage-gated sodium channels as therapeutic targets. Drug Discov. Today 5 (2000) 506-520
36. Cohen-Kaminsky S., and Jambou F. Prospects for a T-cell receptor vaccination against myasthenia gravis. Expert Rev. Vaccines 4 (2005) 473-492
37. Cole R.N., Reddel S.W., Gervásio O.L., and Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann. Neurol. 63 (2008) 782-789
38. Colman J., Rothney A., Wright S.C., Zilkalns B., and Rowe R.H. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 62 (2004) 1695-1700
39. Conte Camerino D., Tortorella V., Ferranini E., and Bryant S.H. The toxic effects of clofibrate and its metabolite on mammalian skeletal muscle: An electrophysiological study. Arch. Toxicol. Suppl. 7 (1984) 482-484
40. Conte Camerino D., De Luca A., Mambrini M., Ferrannini E., Franconi F., Giotti A., and Bryant S.H. The effects of taurine on pharmacologically induced myotonia. Muscle Nerve 12 (1989) 898-904
41. Conte Camerino D., Tricarico D., Pierno S., Desaphy J.F., Liantonio A., Pusch M., Burdi R., Camerino C., Fraysse B., and De Luca A. Taurine and skeletal muscle disorders. Neurochem. Res. 29 (2004) 135-142
42. Conte Camerino D., Tricarico D., and Desaphy J.F. Ion channel pharmacology. Neurotherapeutics 4 (2007) 184-198
43. Conte-Camerino D., Mambrini M., De Luca A., Tricarico D., Bryant S.H., Tortorella V., and Bettoni G. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels. Pflügers Arch. 413 (1988) 105-107
44. Cosford N.D., Bleicher L., Vernier J.M., Chavez-Noriega L., Rao T.S., Siegel R.S., Suto C., Washburn M., Lloyd G.K., and McDonald I.A. Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist. Pharm. Acta Helv. 74 (2000) 125-130
45. Cragg M.S., Walshe C.A., Ivanov A.O., and Glennie M.J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8 (2005) 140-174
46. Dalakas M.C. Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr. Neurol. Neurosci. Rep. 8 (2008) 48-55
47. Dalmau J., Graus F., Villarejo A., Posner J.B., Blumenthal D., Thiessen B., Saiz A., Meneses P., and Rosenfeld M.R. Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 (2004) 1831-1844
48. Damaj M.I., Patrick G.S., Creasy K.R., and Martin B.R. Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 282 (1997) 410-419
49. De Giorgio C.M., Rabinowicz A.L., and Olivas R.D. Carbamazepine-induced antinuclear antibodies and systemic lupus erythematosus-like syndrome. Epilepsia 32 (1991) 128-129
50. De Luca A., Tricarico D., Wagner R., Bryant S.H., Tortorella V., and Conte Camerino D. Opposite effects of enantiomers of clofibric acid derivative on rat skeletal muscle chloride conductance: Antagonism studies and theoretical modeling of two different receptor site interactions. J. Pharmacol. Exp. Ther. 260 (1992) 364-368
51. De Luca A., Tricarico D., Pierno S., and Conte Camerino D. Aging and chloride channel regulation in rat fast-twitch muscle fibres. Pflügers Arch. 427 (1994) 80-85
52. De Luca A., Natuzzi F., Desaphy J.F., Loni G., Lentini G., Franchini C., Tortorella V., and Conte Camerino D. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels. Mol. Pharmacol. 57 (2000) 268-277
53. De Luca A., Talon S., De Bellis M., Desaphy J.F., Lentini G., Corbo F., Scilimiati A., Franchini C., Tortorella V., and Conte Camerino D. Optimal requirements for high affinity and use dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol. Pharmacol. 64 (2003) 932-945
54. Del Fattore A., Cappariello A., and Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 42 (2008) 19-29
55. Desaphy J.F., Conte Camerino D., Franchini C., Lentini G., Tortorella V., and De Luca A. Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na channels in a model of myotonia induced by ATX. Br. J. Pharmacol. 128 (1999) 1165-1174
56. Desaphy J.F., De Luca A., Tortorella P., De Vito D., George Jr. A.L., and Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 57 (2001) 1849-1857
57. Desaphy J.F., Pierno S., De Luca A., Didonna M.P., and Conte Camerino D. Different ability of clenbuterol and salbutamolo to block sodium channels predicts their therapeutic use in muscle excitability disorders. Mol. Pharmacol. 63 (2003) 659-670
58. Desaphy J.F., De Luca A., Didonna M.P., George Jr. A.L., and Conte Camerino D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J. Physiol. 554 (2004) 321-334
59. Desaphy J.F., Rolland J.F., Valente E.M., LoMonaco M., and Conte Camerino D. Functional alteration of ClC-1 channel mutants associated with transient weakness in myotonia congenita. Biophys. J. 92 (2007) 273a (abstract)
60. Deterding R.R., Lavange L.M., Engels J.M., Mathews D.W., Coquillette S.J., Brody A.S., Millard S.P., and Ramsey B.W. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am. J. Respir. Crit. Care Med. 176 (2007) 362-369
61. Diener H.C., Jansen J.P., Reches A., Pascual J., Pitei D., and Steiner T.J. Efficacy, tolerability, and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: A multicenter, randomized, double-blind, placebo-controlled comparison. Eur. Neurol. 47 (2002) 99-107
62. 2+ channel α2δ ligands: Novel modulators of neurotransmission. Trends Pharmacol. Sci. 28 (2007) 75-82
63. Dörner T., and Goldenberg D.M. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther. Clin. Risk Manag. 3 (2007) 953-959
64. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
65. Drachman D.B., Wu J.M., Miagkov A., Williams M.A., Adams R.N., and Wu B. Specific immunotherapy of experimental myasthenia by genetically engineered APCs: The "guided missile" strategy. Ann. N.Y. Acad. Sci. 998 (2003) 520-532
66. Drenth J.P.H., and Waxman S.G. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J. Clin. Invest. 117 (2007) 3603-3609
67. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Kalso E.A., Loeser J.T., Miaskowski C., Nurmikko T.J., et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 132 (2007) 237-250
68. Eguchi H., Tsujino A., Kaibara M., Hayashi H., Shirabe S., Taniyama K., and Eguchi K. Acetazolamide acts directly on the human skeletal muscle chloride channel. Muscle Nerve 34 (2006) 292-297
69. Engel A.G. The therapy of congenital myasthenic syndromes. Neurotherapeutics 4 (2007) 252-257
70. Farrugia M.E., Robson M.D., Clover L., Anslow P., Newsom-Davis J., Kennett R., Hilton-Jones D., Matthews P.M., and Vincent A. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129 (2006) 1481-1492
71. Fell M.J., Johnson B.G., Svensson K.A., and Schoepp D.D. Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. J. Pharmacol. Exp. Ther. 326 (2008) 209-217
72. Fertleman C.R., Baker M.D., Parker K.A., Moffatt S., Elmslie F.V., Abrahamsen B., Ostman J., Klugbauer N., Wood J.N., Gardiner R.M., and Rees M. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 52 (2006) 757-774
73. Fong P. CLC-K channels: If the drug fits, use it. EMBO Rep. 5 (2004) 565-566
74. Gazulla J., and Tintoré M. The P/Q-type voltage-dependent calcium channel: A therapeutic target in spinocerebellar ataxia type 6. Acta Neurol. Scand. 115 (2007) 356-363
75. Grasemann H., Stehling F., Brunar H., Widmann R., Laliberte T.W., Molina L., Döring G., and Ratjen F. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 131 (2007) 1461-1466
76. Gründer S., Firsov D., Chang S.S., Jaeger N.F., Gautschi I., Schild L., Lifton R.P., and Rossier B.C. A mutation causing pseudohypoaldosteronism type 1 identifies a conserved glycine that is involved in the gating of the epithelial sodium channel. EMBO J. 16 (1997) 899-907
77. Gultekin S.H., Rosenfeld M.R., Voltz R., Eichen J., Posner J.B., and Dalmau J. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123 (2000) 1481-1494
78. Hansson J.H., Schild L., Lu Y., Wilson T.A., Gautschi I., Shimkets R., Nelson-Williams C., Rossier B.C., and Lifton R.P. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc. Natl Acad. Sci. USA 92 (1995) 11495-11499
79. Harrower T., Foltynie T., Kartsounis L., De Silva R.N., and Hodges J.R. A case of voltage-gated potassium channel antibody-related limbic encephalitis. Nat. Clin. Pract. Neurol. 2 (2006) 339-343
80. Hart I.K., Maddison P., Newsom-Davis J., Vincent A., and Mills K.R. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 (2002) 1887-1895
81. Harteneck C. Function and pharmacology of TRPM cation channels. Naunyn-Schmied. Arch. Pharmacol. 371 (2005) 307-314
82. Hays J.T., Ebbert J.O., and Sood A. Efficacy and safety of varenicline for smoking cessation. Am. J. Med. 121 Suppl. 1 (2008) S32-S42
83. Heatwole C., and Moxley III R.T. The nondystrophic myotonias. Neurotherapeutics 4 (2007) 238-251
84. Hebert S.C. Bartter syndrome. Curr. Opin. Nephrol. Hypertens. 12 (2003) 527-532
85. Heron S.E., Scheffer I.E., Berkovic S.F., Dibbens L.M., and Mulley J.C. Channelopathies in idiopathic epilepsy. Neurotherapeutics 4 (2007) 295-304
86. Hille B. Ion Channels of Excitable Membranes,. 3rd edn. (2001), Sinauer Associates, Sunderland
87. Hirsh A.J., Molino B.F., Zhang J., Astakhova N., Geiss W.B., Sargent B.J., Swenson B.D., Usyatinsky A., Wyle M.J., Boucher R.C., et al. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: Drugs for cystic fibrosis and chronic bronchitis. J. Med. Chem. 49 (2006) 4098-4115
88. 2+ channels in health and disease. J. Am. Soc. Nephrol. 16 (2005) 15-26
89. Holland K.D., Keamey J.A., Glauser T.A., Buck G., Keddache M., Blankston J.R., Glaaser I.W., Kass R.S., and Meisler M.H. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial paralysis. Neurosci. Lett. 433 (2008) 65-70
90. Imre G. The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev. 13 (2007) 444-464
91. Jacob T.C., Moss S.J., and Jurd R. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat. Rev. Neurosci. 9 (2008) 331-343
92. Jahangir A., and Terzic A. KATP channel therapeutics at the bedside. J. Mol. Cell. Cardiol. 39 (2005) 99-112
93. Jarius S., Paul F., Franciotta D., Waters P., Zipp F., Hohlfeld R., Vincent A., and Wildemann B. Mechanisms of disease: Aquaporin-4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol. 4 (2008) 202-214
94. Jarvis M.F., Honore P., Shieh C.C., Chapman M., Joshi S., Zhang X.F., Kort M., Carroll W., Marron B., Atkinson R., Thomas J., Liu D., et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. USA 104 (2007) 8520-8525
95. Jeck N., Waldegger S., Lampert A., Boehmer C., Waldegger P., Lang P.A., Wissinger B., Friedrich B., Risler T., Moehle R., Lang U.E., Zill P., et al. Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension 43 (2004) 1175-1181
96. Jentsch T.J. CLC chloride channels and transporters: From genes to protein structure, pathology and physiology. Crit. Rev. Biochem. Mol. Biol. 43 (2008) 3-36
97. Jurkat-Rott K., and Lehmann-Horn F. Muscle channelopathies and critical points in functional and genetic studies. J. Clin. Invest. 115 (2005) 2000-2009
98. Jurkat-Rott K., and Lehmann-Horn F. Do hyperpolarization induced proton currents contribute to the pathogenesis of hypokalemic periodic paralysis, a voltage sensor channelopathy?. J. Gen. Physiol. 130 (2007) 1-5
99. Kalamida D., Poulas K., Avramopoulou V., Fostieri E., Lagoumintzis K., Sideri A., Zouridakis M., and Tzartos S.J. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS J. 274 (2007) 3799-3845
100. Karsdal M.A., Henriksen K., Sørensen M.G., Gram J., Schaller S., Dziegiel M.H., Heegaard A.M., Christophersen P., Martin T.J., Christiansen C., et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am. J. Pathol. 166 (2005) 467-476
101. Kasper D., Planells-Cases R., Fuhrmann J.C., Scheel O., Zeitz O., Ruether K., Schmitt A., Poët M., Steinfeld R., Schweizer M., Kornak U., and Jentsch T.J. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J. 24 (2005) 1079-1091
102. Kazkaz H., and Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr. Opin. Pharmacol. 4 (2004) 398-402
103. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Shibasaki H., Kume T., and Akaike A. Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J. Biol. Chem. 276 (2001) 13541-13546
104. Kleta R., and Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol. 104 (2006) 73-80
105. Konrad M., Vollmer M., Lemmink H.H., van den Heuvel L.P., Jeck N., Vargas-Poussou R., Lakings A., Ruf R., Deschênes G., Antignac C., Guay-Woodford L., Knoers N.V., et al. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J. Am. Soc. Nephrol. 11 (2000) 1449-1459
106. Kordasiewicz H.B., and Gomez C.M. Molecular pathogenesis of spinocerebellar ataxia type 6. Neurotherapeutics 4 (2007) 285-294
107. Kornak U., Kasper D., Bösl M.R., Kaiser E., Schweizer M., Schulz A., Friedrich W., Delling G., and Jentsch T.J. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104 (2001) 205-215
108. Kort M.E., Drizin I., Gregg R.J., Scanio M.J., Shi L., Gross M.F., Atkinson R.N., Johnson M.S., Pacofsky G.J., Thomas J.B., Carroll W.A., Krambis M.J., et al. Discovery and biological evaluation of 5-ary1-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem. 51 (2008) 407-416
109. Krause T., Gerbershagen M.U., Fiege M., Weißhorn R., and Wappler F. Dantrolene-A review of its pharmacology, therapeutic use and new developments. Anaesthesia 59 (2004) 364-373
110. + current by diphenhydramine and other diphenyl compounds: Molecular determinants of selective binding to the inactivated channels. Mol. Pharmacol. 57 (2000) 135-143
111. Lacy B.E., and Levy L.C. Lubiprostone: A chloride channel activator. J. Clin. Gastroenterol. 41 (2007) 345-351
112. Lange P.F., Wartosch L., Jentsch T.J., and Fuhrmann J.C. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 440 (2006) 220-223
113. Legroux-Crespel E., Sassolas B., Guillet G., Kupfer I., Dupre D., and Misery L. Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Ann. Dermatol. Venereol. 130 (2003) 429-433
114. Lehnart S.E., Ackerman M.J., Benson Jr. D.W., Brugada R., Clancy C.E., Donahue J.K., George Jr. A.L., Grant A.O., Groft S.C., January C.T., Lathrop D.A., Lederer W.J., et al. Inherited arrhythmias: A national Heart, lung, and blood institute and office of rare diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 116 (2007) 2325-2345
115. Lenkey N., Karoly R., Kiss J.P., Szasz B.K., Vizi E.S., and Mike A. The mechanism of activity-dependent sodium channel inhibition by the antidepressants fluoxetine and desipramine. Mol. Pharmacol. 70 (2006) 2052-2063
116. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., and Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202 (2005) 473-477
117. Liantonio A., Accardi A., Carbonara G., Fracchiolla G., Loiodice F., Tortorella P., Traverso S., Guida P., Pierno S., De Luca A., Conte Camerino D., and Pusch M. Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alky1 derivatives of 2-(p-chlorophenoxy)propionic acid. Mol. Pharmacol. 62 (2002) 265-271
118. Liantonio A., De Luca A., Pierno S., Didonna M.P., Loiodice F., Fracchiolla G., Tortorella P., Laghezza A., Bonerba E., Traverso S., Elia L., Picollo A., et al. Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1. Br. J. Pharmacol. 139 (2003) 1255-1264
119. Liantonio A., Pusch M., Picollo A., Guida P., De Luca A., Pierno S., Fracchiolla G., Loiodice F., Tortorella P., and Conte Camerino D. Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers. J. Am. Soc. Nephrol. 15 (2004) 13-20
120. Liantonio A., Picollo A., Babini E., Carbonara G., Fracchiolla G., Loiodice F., Tortorella V., Pusch M., and Conte Camerino D. Activation and inhibition of kidney CLC-K chloride channels by fenamates. Mol. Pharmacol. 69 (2006) 165-173
121. Liantonio A., Giannuzzi V., Picollo A., Babini E., Pusch M., and Conte Camerino D. Niflumic acid inhibits chloride conductance of rat skeletal muscle by directly inhibiting the CLC-1 channel and by increasing intracellular calcium. Br. J. Pharmacol. 150 (2007) 235-247
122. Liantonio A., Picollo A., Carbonara G., Fracchiolla G., Tortorella P., Loiodice F., Laghezza A., Babini E., Zifarelli G., Pusch M., and Conte Camerino D. Molecular switch for CLC-K CL-channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands. Proc. Natl. Acad. Sci. USA 105 (2008) 1369-1373
123. Liguori R., Vincent A., Clover L., Avoni P., Plazzi G., Cortelli P., Baruzzi A., Carey T., Gambetti P., Lugaresi E., and Montagna P. Morvan's syndrome: Peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 (2001) 2417-2426
124. Links T.P., Smit A.J., and Reitsma W.D. Potassium channel modulation: Effect of pinacidil on insulin release in healthy volunteers. J. Clin. Pharmacol. 35 (1995) 291-294
125. Lipkind G.M., and Fozzard H.A. Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol. Pharmacol. 68 (2005) 1611-1622
126. Lloyd S.E., Pearce S.H., Fisher S.E., Steinmeyer K., Schwappach B., Scheinman S.J., Harding B., Bolino A., Devoto M., Goodyer P., Rigden S.P., Wrong O., et al. A common molecular basis for three inherited kidney stone diseases. Nature 379 (1996) 445-449
127. Lu M., Echeverri F., Kalabat D., Laita B., Dahan D.S., Smith R.D., Xu H., Staszewski L., Yamamoto J., Ling J., Hwang N., Kimmich R., et al. Small molecule activator of the human epithelial sodium channel. J. Biol. Chem. 283 (2008) 11981-11994
128. Lucas P.T., Meadows L.S., Nicholls J., and Ragsdale D.S. An epilepsy mutation in the β1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res. 64 (2005) 77-84
129. Ludwig M., Utsch B., Balluch B., Fründ S., Kuwertz-Bröking E., and Bökenkamp A. Hypercalciuria in patients with CLCN5 mutations. Pediatr. Nephrol. 21 (2006) 1241-1250
130. Lykke Thomsen L., Kirchmann Eriksen M., Faerch Romer S., Andersen I., Ostergaard E., Keiding N., Olesen J., and Russell M.B. An epidemiological survey of hemiplegic migraine. Cephalalgia 22 (2002) 361-375
131. Makielski J.C., and Valdivia C.R. Ranolazine and late cardiac sodium current-A therapeutic target for angina, arrhythmia and more?. Br. J. Pharmacol. 148 (2006) 4-6
132. Makita N., Behr E., Shimizu W., Horie M., Sunami A., Crotti L., Schulze-Bahr E., Fukuhara S., Mochizuki N., Makiyama T., Itoh H., Christiansen M., et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J. Clin. Invest. 118 (2008) 2219-2229
133. Matsuda S., and Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 47 (2000) 119-125
134. Miceli F., Soldovieri M.V., Martire M., and Tagliatatela M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr. Opin. Pharmacol. 8 (2008) 65-74
135. Mukerji N., Damodaran T.V., and Winn M.P. TRPC6 and FSGS: The latest TRP channelopathy. Biochim. Biophys. Acta 1772 (2007) 859-868
136. Naderi A.S., and Reilly Jr. R.F. Hereditary etiologies of hypomagnesemia. Nat. Clin. Pract. Nephrol. 4 (2008) 80-89
137. Naesens M., Steels P., Verberckmoes R., Vanrenterghem Y., and Kuypers D. Bartter's and Gitelman's syndromes: From gene to clinic. Nephron Physiol. 96 (2004) 65-78
138. Nichols C.G. KATP channels as molecular sensors of cellular metabolism. Nature 440 (2006) 470-476
139. Nissant A., Lourdel S., Baillet S., Paulais M., Marvao P., Teulon J., and Imbert-Teboul M. Heterogeneous distribution of chloride channels along the distal convoluted tubule probed by single-cell RT-PCR and patch clamp. Am. J. Physiol. Renal. Physiol. 287 (2004) F1233-F1243
140. Olive M.F. Interactions between taurine and ethanol in the central nervous system. Amino Acids 23 (2002) 345-357
141. O'Shaughnessy K.M., and Karet F.E. Salt handling and hypertension. J. Clin. Invest. 113 (2004) 1075-1081
142. O'Shea S.M., Becker L., Weiher H., Betz H., and Laube B. Propofol restores the function of hyperekplexic mutant glycine receptors in Xenopus oocytes and mice. J. Neurosci. 24 (2004) 2322-2327
143. Pascuzzi R.M., Coslett H.B., and Johns T.R. Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients. Ann. Neurol. 15 (1984) 291-298
144. Perucca E., French J., and Bialer M. Development of new antiepileptic drugs: Challenges, incentives, and recent advances. Lancet Neurol. 6 (2007) 793-804
145. Picard F., Bertrand S., Steinlein O.K., and Bertrand D. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 40 (1999) 1198-1209
146. Picollo A., and Pusch M. Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 436 (2005) 420-423
147. Picollo A., Liantonio A., Didonna M.P., Elia L., Conte Camerino D., and Pusch M. Molecular determinants of differential pore blocking of kidney CLC-K chloride channels. EMBO Rep. 5 (2004) 584-589
148. Picollo A., Liantonio A., Babini E., Conte Camerino D., and Pusch M. Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J. Membr. Biol. 216 (2007) 73-82
149. Piddlesden S.J., Jiang S., Levin J.L., Vincent A., and Morgan B.P. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71 (1996) 173-177
150. Pierno S., Didonna M.P., Cippone V., De Luca A., Pisoni M., Frigeri A., Nicchia G.P., Svelto M., Chiesa G., Sirtori C., Scanziani E., Rizzo C., et al. Effects of chronic treatment with stains and fenofibrate on rat skeletal muscle: A biochemical, histological and electrophysiological study. Br. J. Pharmacol. 149 (2006) 909-919
151. Pierno S., De Luca A., Desaphy J.F., Fraysse B., Liantonio A., Didonna M.P., Lograno M., Cocchi D., Smith R.G., and Conte Camerino D. Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor. Br. J. Pharmacol. 139 (2003) 575-584
152. Pierno S., Didonna M.P., Cippone V., De Luca A., Pisoni M., Frigeri A., Nicchia G.P., Svelto M., Chiesa G., Sirtori C., et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: A biochemical, histological and electrophysiological study. Br. J. Pharmacol. 149 (2006) 909-919
153. Pierno S., Camerino G.M., Liantonio A., Cippone V., De Luca A., Giannuzzi V., Kunic J., George A.L., and Conte Camerino D. Molecular mechanisms responsible for fluvastatin and fenofibrate-induced reduction of resting membrane chloride conductance in rat skeletal muscle. Biophys. J. 92 (2007) 274a (abstract)
154. Piper S.N., Triem J.G., Maleck W.H., Fent M.T., Hüttner I., and Boldt J. Placebo-controlled comparison of dolasetron and metoclopramide in preventing postoperative nausea and vomiting in patients undergoing hysterectomy. Eur. J. Anaesthesiol. 18 (2001) 251-256
155. Priest B.T., and Kaczorowski G.J. Blocking sodium channels to treat neuropathic pain. Exp. Opin. Ther. Targets 11 (2007) 291-306
156. Priori S.G., Napolitano C., Schwartz P.J., Bloise R., Crotti L., and Ronchetti E. The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge. Circulation 102 (2000) 945-947
157. Proesmans M., Vermeulen F., and De Boeck K. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur. J. Pediatr. 167 (2008) 839
158. Pusch M. Myotonia caused by mutations in the muscle chloride channel gene ClCN1. Hum. Mutat. 19 (2002) 423-434
159. Pusch M., Liantonio A., Bertorello L., Accardi A., De Luca A., Pierno S., Tortorella V., and Camerino D.C. Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives. Mol. Pharmacol. 58 (2000) 498-507
160. Pusch M., Accardi A., Liantonio A., Ferrera L., De Luca A., Camerino D.C., and Conti F. Mechanism of block of single protopores of the Torpedo chloride channel ClC-0 by 2-(p-chlorophenoxy)butyric acid (CPB). J. Gen. Physiol. 118 (2001) 45-62
161. + channel openers suppress myotonic activity of human skeletal muscle in vitro. Eur. J. Pharmacol. 186 (1990) 125-128
162. Ragsdale D.S. How do mutant Nav1.1 sodium channels cause epilepsy?. Brain Res. Rev. 58 (2008) 149-159
163. + channels. Proc. Natl Acad. Sci. USA 93 (1996) 9270-9275
164. Rajakulendran S., Schorge S., Kullmann D.M., and Hanna M.G. Episodic ataxia type 1: A neuronal potassium channelopathy. Neurotherapeutics 4 (2007) 258-266
165. Ramírez A., Faupel J., Goebel I., Stiller A., Beyer S., Stöckle C., Hasan C., Bode U., Kornak U., and Kubisch C. Identification of a novel mutation in the coding region of the grey-lethal gene OSTM1 in human malignant infantile osteopetrosis. Hum. Mutat. 23 (2004) 471-476
166. Reinalter S.C., Jeck N., Brochhausen C., Watzer B., Nusing R.M., Seyberth H.W., and Komhoff M. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 62 (2002) 253-260
167. Rodgers H.C., and Knox A.J. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur. Respir. J. 14 (1999) 693-696
168. Rolland J.F., Tricarico D., Laghezza A., Loiodice F., Tortorella V., and Camerino D.C. A new benzoxazine compound blocks KATP channels in pancreatic beta cells: Molecular basis for tissue selectivity in vitro and hypoglycaemic action in vivo. Br. J. Pharmacol. 149 (2006) 870-879
169. Rosenbohm A., Rüdel R., and Fahlke C. Regulation of the human skeletal muscle chloride channel hClC-1 by protein kinase C. J. Physiol. 514 (1999) 677-685
170. Rowe S.M., Miller S., and Sorscher E.J. Cystic fibrosis. N. Engl. J. Med. 352 (2005) 1992-2001
171. Ruan Y., Liu N., Bloise R., Napolitano C., and Priori S.G. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 116 (2007) 1137-1144
172. Sanders D.B., El-Salem K., Massey J.M., McConville J., and Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60 (2003) 1978-1980
173. Sanguinetti M.C., and Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 440 (2006) 463-469
174. Sansone V., and Tawil R. Management and treatment of Andersen-Tawil syndrome (ATS). Neurotherapeutics 4 (2007) 233-237
175. Schaller S., Henriksen K., Sveigaard C., Heegaard A.M., Hélix N., Stahlhut M., Ovejero M.C., Johansen J.V., Solberg H., Andersen T.L., et al. The chloride channel inhibitor NS3736 prevents bone resorption in ovariectomized rats without changing bone formation. J. Bone Miner. Res. 19 (2004) 1144-1153
176. Scheel O., Zdebik A.A., Lourdel S., and Jentsch T.J. Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436 (2005) 424-427
177. Schlingmann K.P., Weber S., Peters M., Niemann Nejsum L., Vitzthum H., Klingel K., Kratz M., Haddad E., Ristoff E., Dinour D., Syrrou M., Nielsen S., et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat. Genet. 31 (2002) 166-170
178. Schneider J.S., Van Velson M., Menzaghi F., and Lloyd G.K. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment. Ann. Neurol. 43 (1998) 311-317
179. Schneider-Gold C., Gajados P., Toyka K.V., and Hohlfeld R.R. Corticosteroids for myasthenia gravis. Cochrane Database Syst. Rev. 2, (2005) CD002828
180. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 92 (1995) 3381-3386
181. v1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J. Physiol. 581 3 (2007) 1019-1031
182. Shillito P., Molenaar P.C., Vincent A., Leys K., Zheng W., van den Berg R.J., Plomp J.J., van Kempen G.T.H., Chauplannaz G., Wintzen A.R., van Dijk J.G., and Newsom-Davis J. Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann. Neurol. 38 (1995) 714-722
183. Shimizu W., Aiba T., and Antzelevitch C. Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias Long QT syndrome and Brugada syndrome. Curr. Pharm. Des. 11 (2005) 1561-1572
184. Silberstein S.D. Preventive treatment of migraine. Trends Pharmacol. Sci. 27 (2006) 410-415
185. Simard J.M., Woo K.S., Bhatta S., and Gerzanich V. Drugs acting on SUR1 to treat CNS ischemia and trauma. Curr. Opin. Pharmacol. 8 (2008) 42-49
186. Singer W., Opfer-Gehrking T.L., McPhee B.R., Hilz M.J., Bharucha A.E., and Low P.A. Acetylcholinesterase inhibition: A novel approach in the treatment of neurogenic orthostatic hypotension. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1294-1298
187. + channel. Cell 83 (1995) 969-978
188. Soreq H., and Seidman S. Anti-sense approach to anticholinesterase therapeutics. Isr. Med. Assoc. J. 2 Suppl. (2000) 81-85
189. Steinlein O.K. Genetic mechanisms that underlie epilepsy. Nat. Rev. Neurosci. 5 (2004) 400-408
190. Steinmeyer K., Ortland C., and Jentsch T.J. Primary structure and functional expression of a developmentally regulated skeletal muscle chloride channel. Nature 354 (1991) 301-304
191. Striano P., Coppola A., Pezzella M., Ciampa C., Specchio N., Ragona F., Mancarde M.M., Gennaro E., Beccaria F., Capovilla G., Rasmini P., Befana D., et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 69 (2007) 250-254
192. Strupp M., Zwergal A., and Brandt T. Episodic ataxia type 2. Neurotherapeutics 4 (2007) 267-275
193. + channel. J. Physiol. 537 (2001) 701-714
194. Tate S.K., Depondt C., Sisodiya S.M., Cavalleri G.L., Schorge S., Soranzo N., Thom M., Sen A., Shorvon S.D., Sander J.W., Wood N.W., and Goldstein D.B. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl. Acad. Sci. USA 102 (2005) 5507-5512
195. Tawil R., McDermott M.P., Brown Jr. R., Shapiro B.C., Ptacek L.J., McManis P.G., Dalakas M.C., Spector S.A., Mendell J.R., Hahn A.F., and Griggs R.C. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann. Neurol. 47 (2000) 46-53
196. Teulon J., Lourdel S., Nissant A., Paulais M., Guinamard R., Marvao P., and Imbert-Teboul M. Exploration of the basolateral chloride channels in the renal tubule using. Nephron Physiol. 99 (2005) 64-68
197. Thiry A., Dogné J.M., Supuran C.T., and Marercel B. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: Drug design and mechanism of action. Curr. Pharm. Des. 14 (2008) 661-671
198. Timerman A.P., Ogunbumni E., Freund E., Wiederrecht G., Marks A.R., and Fleischer S. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 268 (1993) 22992-22999
199. + depleted rat, an animal model of hypokalemic periodic paralysis. Mol. Pharmacol. 54 (1998) 197-206
200. + channels in patients with hypokalemic periodic paralysis. J. Clin. Invest. 103 (1999) 675-682
201. Tricarico D., Barbieri M., Antonio L., Tortorella P., Loiodice F., and Conte Camerino D. Dualistic actions of cromakalim and new potent 2H-1,4-benzoxazine derivatives on the native skeletal muscle KATP channel. Br. J. Pharmacol. 139 (2003) 255-262
202. +-deficient rats. FASEB J. 18 (2004) 760-761
203. + channels. Neuromuscul. Disord. 16 (2006) 39-45
204. + channels determine their muscle type-dependent biophysical and pharmacological properties. Proc. Natl Acad. Sci. USA 103 (2006) 1118-1123
205. Tricarico D., Lovaglio S., Mele A., Rotondo G., Mancinelli E., Meola G., and Conte Camerino D. Acetazolamide prevents vacuolar myopathy in skeletal muscle of K-depleted rats. Br. J. Pharmacol. 154 (2008) 183-190
206. +-depleted rats. Neuromuscul. Disord. 18 1 (2008) 74-80
207. Trip J., Drost G., van Engelen B.G., and Faber C.G. Drug treatment for myotonia. Cochrane Database Syst. Rev. 25, (2006) CD004762
208. Trudeau M.M., Dalton J.C., Day J.W., Ranum L.P., and Meisler M.H. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J. Med. Genet. 43 (2006) 527-530
209. Ubiali F., Nava S., Nessi V., Longhi R., Pezzoni G., Capobianco R., Mantegazza R., Antozzi C., and Baggi F. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. J. Immunol. 180 (2008) 2696-2703
210. Unwin R.J., and Capasso G. Bartter's and Gitelman's syndromes: Their relationship to the actions of loop and thiazide diuretics. Curr. Opin. Pharmacol. 6 (2006) 208-213
211. Venance S.L., Cannon S.C., Fialho D., Fontaine B., Hanna M.G., Ptacek L.J., Tristani-Firouzi M., Tawil R., Griggs R.C., a., and CINCH Investigators. The primary periodic paralyses: Diagnosis, pathogenesis and treatment. Brain 129 (2006) 8-17
212. Venance S.L., Herr B.E., and Griggs R.C. Challenges in the design and conduct of therapeutic trials in channel disorders. Neurotherapeutics 4 (2007) 199-204
213. Vernino S. Autoimmune and paraneoplastic channelopathies. Neurotherapeutics 4 (2007) 305-314
214. Vernino S., Sandroni P., Singer W., and Low P.A. Invited article: Autonomic ganglia: Target and novel therapeutic tool. Neurology 70 (2008) 1926-1932
215. Vidic-Dankovic B., Kosec D., Damjanovic M., Apostolski S., Isakovic K., and Bartlett R.R. Leflunomide prevents the development of experimentally induced myasthenia gravis. Int. J. Immunopharmacol. 17 (1995) 273-281
216. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., and Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
217. Walder R.Y., Landau D., Meyer P., Shalev H., Tsolia M., Borochowitz Z., Boettger M.B., Beck G.E., Englehardt R.K., Carmi R., and Sheffield V.C. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet. 31 (2002) 171-174
218. Walz W. Chloride/anion channels in glial cell membranes. Glia 40 (2002) 1-10
219. Wang D.W., Yazawa K., Makita N., George Jr. A.L., and Bennett P.B. Pharmacological targeting of long QT mutant sodium channels. J. Clin. Invest. 99 (1997) 1714-1720
220. Wang L., Kinnear C., Hammel J.M., Zhu W., Hua Z., Mi W., and Caldarone C.A. Preservation of mitochondrial structure and function after cardioplegic arrest in the neonate using a selective mitochondrial KATP channel opener. Ann. Thorac. Surg. 81 (2006) 1817-1823
221. Watanabe H., Koopmann T.T., Le Scouarnec S., Yang T., Ingram C.R., Schott J.J., Demolombe S., Probst V., Anselme F., Escande D., et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J. Clin. Invest. 118 (2008) 2260-2268
222. Webb T.I., and Lynch J.W. Molecular pharmacology of the glycine receptor chloride channel. Curr. Pharm. Des. 13 (2007) 2350-2367
223. Weinstock-Guttman B., Ramanathan M., Lincoff N., Napoli S.Q., Sharma J., Feichter J., and Bakshi R. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. 63 (2006) 957-963
224. Winn M.P., Conlon P.J., Lynn K.L., Farrington M.K., Creazzo T., Hawkins A.F., Daskalakis N., Kwan S.Y., Ebersviller S., Burchette J.L., Pericak-Vance M.A., Howell D.N., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308 (2005) 1801-1804
225. Wintzen A.R., Lammers J.G., and van Dijk J.G. Does modafinil enhance activity of patients with myotonic dystrophy? A double-blind placebo-controlled crossover study. J. Neurol. 254 (2007) 26-28
226. + channel is mediated by inhibiting the mitochondrial permeability transition pore. Neurosci. Lett. 402 (2006) 184-189
227. Yadava R.S., Frenzel-McCardell C.D., Yu Q., Srinivasan V., Tucker A.L., Puymirat J., Thornton C.A., Prall O.W., Harvey R.P., and Mahadevan M.S. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat. Genet. 40 (2008) 61-68
228. Yarov-Yarovoy V., McPhee J.C., Idswoog D., Pate C., Scheuer T., and Catterall W.A. Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na channel α-subunit in voltage-dependent gating and drug block. J. Biol. Chem. 277 (2002) 35393-35401
229. Zaja F., Russo D., Fuga G., Perella G., and Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55 (2000) 1062-1063
230. Zeitlin P.L., Boyle M.P., Guggino W.B., and Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 125 (2004) 143-149
231. Zeng H., Lozinskaya I.M., Lin Z., Willette R.N., Brooks D.P., and Xu X. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J. Pharmacol. Exp. Ther. 319 (2006) 957-962
232. Zhou L., Chillag K.L., and Nigro M.A. Hyperekplexia: A treatable neurogenetic disease. Brain Dev. 24 (2002) 669-674
233. Zipes D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M., Gregoratos G., Klein G., Moss A.J., Myerburg R.J., Priori S.G., Quinones M.A., et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-Executive summary. Circulation 114 (2006) 1088-1132
234. Zünkler B.J. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol. Ther. 112 (2006) 12-37